Valneva SE (VALN) has a near-term catalyst to watch related to its tetravalent Shigella vaccine candidate, S4V2, developed in partnership with LimmaTech Biologics.
Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide, responsible for an estimated 600,000 deaths annually, particularly among children in low-and middle-income countries. Despite this burden, no approved Shigella vaccine currently exists, making S4V2 the most clinically advanced candidate in development.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com